Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Price, Quote, News and Overview

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.26  +0.16 (+14.55%)

After market: 1.31 +0.05 (+3.97%)

PYXS Quote, Performance and Key Statistics

PYXIS ONCOLOGY INC

NASDAQ:PYXS (5/2/2025, 4:32:25 PM)

After market: 1.31 +0.05 (+3.97%)

1.26

+0.16 (+14.55%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.39
52 Week Low0.83
Market Cap77.60M
Shares61.59M
Float46.79M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-09 2025-05-09/bmo
IPO10-08 2021-10-08


PYXS short term performance overview.The bars show the price performance of PYXS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60

PYXS long term performance overview.The bars show the price performance of PYXS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of PYXS is 1.26 USD. In the past month the price increased by 34.69%. In the past year, price decreased by -71.23%.

PYXIS ONCOLOGY INC / PYXS Daily stock chart

PYXS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.56B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About PYXS

Company Profile

PYXS logo image Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Company Info

PYXIS ONCOLOGY INC

321 Harrison Avenue

Boston MASSACHUSETTS US

Employees: 55

Company Website: https://pyxisoncology.com/

Investor Relations: http://ir.pyxisoncology.com

Phone: 16172219059

PYXIS ONCOLOGY INC / PYXS FAQ

What is the stock price of PYXIS ONCOLOGY INC today?

The current stock price of PYXS is 1.26 USD. The price increased by 14.55% in the last trading session.


What is the ticker symbol for PYXIS ONCOLOGY INC stock?

The exchange symbol of PYXIS ONCOLOGY INC is PYXS and it is listed on the Nasdaq exchange.


On which exchange is PYXS stock listed?

PYXS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PYXIS ONCOLOGY INC stock?

14 analysts have analysed PYXS and the average price target is 7.34 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 1.26. Check the PYXIS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PYXIS ONCOLOGY INC worth?

PYXIS ONCOLOGY INC (PYXS) has a market capitalization of 77.60M USD. This makes PYXS a Micro Cap stock.


How many employees does PYXIS ONCOLOGY INC have?

PYXIS ONCOLOGY INC (PYXS) currently has 55 employees.


Is PYXIS ONCOLOGY INC (PYXS) expected to grow?

The Revenue of PYXIS ONCOLOGY INC (PYXS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PYXS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PYXIS ONCOLOGY INC (PYXS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PYXIS ONCOLOGY INC (PYXS) stock pay dividends?

PYXS does not pay a dividend.


When does PYXIS ONCOLOGY INC (PYXS) report earnings?

PYXIS ONCOLOGY INC (PYXS) will report earnings on 2025-05-09, before the market open.


What is the Price/Earnings (PE) ratio of PYXIS ONCOLOGY INC (PYXS)?

PYXIS ONCOLOGY INC (PYXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).


What is the Short Interest ratio of PYXIS ONCOLOGY INC (PYXS) stock?

The outstanding short interest for PYXIS ONCOLOGY INC (PYXS) is 15.24% of its float. Check the ownership tab for more information on the PYXS short interest.


PYXS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to PYXS. When comparing the yearly performance of all stocks, PYXS is a bad performer in the overall market: 92.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PYXS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PYXS. The financial health of PYXS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PYXS Financial Highlights

Over the last trailing twelve months PYXS reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 48.65% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -49.2%
ROE -64.04%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%24.24%
Sales Q2Q%N/A
EPS 1Y (TTM)48.65%
Revenue 1Y (TTM)N/A

PYXS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to PYXS. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -20.25% and a revenue growth -100% for PYXS


Ownership
Inst Owners41.24%
Ins Owners7.68%
Short Float %15.24%
Short Ratio12.29
Analysts
Analysts85.71
Price Target7.34 (482.54%)
EPS Next Y-20.25%
Revenue Next Year-100%